Mitomycin intravesicular - UroGen

Drug Profile

Mitomycin intravesicular - UroGen

Alternative Names: MitoGel™; Mitomycin C mixed with TC Gel; Mitomycin C mixed with TC-3 gel; MMC gel; VesiGel™

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TheraCoat
  • Developer UroGen Pharma
  • Class Antineoplastics; Aziridines; Carbamates; Cytostatic antibiotics; Indoles; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Urogenital cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Bladder cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Bladder-cancer in India (Intravesicular, Liquid)
  • 29 Aug 2017 Mitomycin intravesicular - UroGen receives Fast Track designation for low-grade upper tract urothelial carcinoma (UTUC) [Intravesicular,Liquid] in USA
  • 15 Jun 2017 TheraCoat completes a phase II trial for Bladder cancer (Neoadjuvant therapy) in Israel (NCT02307487)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top